News

Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)

Cerdulatinib is an oral, dual Syk-JAK kinase inhibitor that Portola is developing to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded

The data included in the MAA support the use of F/TAF to treat HIV-1 infection in adults in combination with other HIV antiretroviral agents. TAF is a new

Cannabics’ team of scientists has developed a high throughput screening system which is specifically designed to give personalized antitumor treatments to cancer patients. In this proprietary system, biopsies

Ace-ER is designed to replace the deficient sialic acid substrate in patients with GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), a rare, progressive muscle-wasting disease.

In an effort to improve the quality of life for patients suffering from this debilitating disorder, a research team of investigators at Boehringer Ingelheim, the Universities of Michigan

This catalog and its associated materials are called the Amgen Biology-Enabling Resource (AmBER). AmBER is comprised of more than 1,000 elements and includes small molecules, peptides, antibodies and

In patients with active cancer, the risk of venous thromboembolism (VTE) is four to seven times higher than in people of the same age without cancer, while chemotherapy

Under the multi-year program, the company will award a total of about $3m in grants to investigators in the US. This program is an extension of the company’s